KR102738936B1 - 골수증식 장애의 치료 방법 - Google Patents

골수증식 장애의 치료 방법 Download PDF

Info

Publication number
KR102738936B1
KR102738936B1 KR1020217019508A KR20217019508A KR102738936B1 KR 102738936 B1 KR102738936 B1 KR 102738936B1 KR 1020217019508 A KR1020217019508 A KR 1020217019508A KR 20217019508 A KR20217019508 A KR 20217019508A KR 102738936 B1 KR102738936 B1 KR 102738936B1
Authority
KR
South Korea
Prior art keywords
subject
pharmaceutical composition
composition according
ruxolitinib
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217019508A
Other languages
English (en)
Korean (ko)
Other versions
KR20210095904A (ko
Inventor
아드리안 센더로비츠
마이클 쿠퍼
Original Assignee
콘스텔레이션 파마슈티칼스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 콘스텔레이션 파마슈티칼스, 인크. filed Critical 콘스텔레이션 파마슈티칼스, 인크.
Priority to KR1020247040010A priority Critical patent/KR20250004357A/ko
Publication of KR20210095904A publication Critical patent/KR20210095904A/ko
Application granted granted Critical
Publication of KR102738936B1 publication Critical patent/KR102738936B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
KR1020217019508A 2018-11-27 2018-11-27 골수증식 장애의 치료 방법 Active KR102738936B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020247040010A KR20250004357A (ko) 2018-11-27 2018-11-27 골수증식 장애의 치료 방법

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2018/062534 WO2020112086A1 (en) 2018-11-27 2018-11-27 Methods of treating myeloproliferative disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020247040010A Division KR20250004357A (ko) 2018-11-27 2018-11-27 골수증식 장애의 치료 방법

Publications (2)

Publication Number Publication Date
KR20210095904A KR20210095904A (ko) 2021-08-03
KR102738936B1 true KR102738936B1 (ko) 2024-12-06

Family

ID=64734125

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020217019508A Active KR102738936B1 (ko) 2018-11-27 2018-11-27 골수증식 장애의 치료 방법
KR1020247040010A Pending KR20250004357A (ko) 2018-11-27 2018-11-27 골수증식 장애의 치료 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020247040010A Pending KR20250004357A (ko) 2018-11-27 2018-11-27 골수증식 장애의 치료 방법

Country Status (8)

Country Link
JP (2) JP7453230B2 (https=)
KR (2) KR102738936B1 (https=)
AU (1) AU2018451360B2 (https=)
BR (1) BR112021010134A2 (https=)
CA (1) CA3120973A1 (https=)
EA (1) EA202191489A1 (https=)
SG (1) SG11202105279SA (https=)
WO (1) WO2020112086A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021006205A (es) 2018-11-27 2021-10-13 Constellation Pharmaceuticals Inc Metodos de tratamiento de trastornos mieloproliferativos.
EA202191489A1 (ru) * 2018-11-27 2021-09-10 Констеллейшен Фармасьютикалс, Инк. Способы лечения миелопролиферативных расстройств
CN114761013A (zh) 2019-09-27 2022-07-15 迪斯克医药公司 治疗骨髓纤维化和相关病症的方法
WO2021231798A1 (en) 2020-05-13 2021-11-18 Disc Medicine, Inc. Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
IL300337A (en) * 2020-08-04 2023-04-01 Constellation Pharmaceuticals Inc 2-((4S)-6-(4-chlorophenyl)-1-methyl-4H-benzo[C]isoxazolo[5,4-E]azepin-4-yl)acetamide for the treatment of thrombocythemia
WO2025155120A1 (ko) 2024-01-18 2025-07-24 주식회사 엘지에너지솔루션 전극조립체, 이차 전지 및 배터리 유닛

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR084070A1 (es) * 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
CA2952830C (en) 2014-06-20 2022-11-01 Constellation Pharmaceuticals, Inc. Crystalline forms of 2-((4s)-6-(4-chlorophenyl)-1-methyl-4h-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide
EA202191489A1 (ru) * 2018-11-27 2021-09-10 Констеллейшен Фармасьютикалс, Инк. Способы лечения миелопролиферативных расстройств

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Cancer cell, 2018, 33(1), 29-43*
Journal of Medicinal Chemistry, 2016, 59, 1330-1339*

Also Published As

Publication number Publication date
WO2020112086A1 (en) 2020-06-04
KR20250004357A (ko) 2025-01-07
AU2018451360A1 (en) 2021-06-10
JP2024063214A (ja) 2024-05-10
CA3120973A1 (en) 2020-06-04
SG11202105279SA (en) 2021-06-29
EA202191489A1 (ru) 2021-09-10
AU2018451360B2 (en) 2022-05-26
JP2022519425A (ja) 2022-03-24
KR20210095904A (ko) 2021-08-03
BR112021010134A2 (pt) 2021-08-24
JP7453230B2 (ja) 2024-03-19

Similar Documents

Publication Publication Date Title
KR102738936B1 (ko) 골수증식 장애의 치료 방법
US12070464B2 (en) Methods of treating myeloproliferative disorders
US20220168333A1 (en) Combination Treatment for Hematological Cancers
MX2012014416A (es) Tratamiento de cancer de sangre.
US20150110774A1 (en) S100 protein inhibitors for treating leukemia
WO2021091535A1 (en) Treating myeloproliferative disorders with cpi-0610 and a jak inhibitor
US20240269146A1 (en) Use of pelabresib for treating anemias
EA047870B1 (ru) Способы лечения миелопролиферативных расстройств
KR20230110751A (ko) 골수섬유증의 치료에 사용하기 위한 cxcr1/cxcr2 억제제
WO2021091532A1 (en) Methods of treating myeloproliferative disorders
WO2020256739A1 (en) Methods of treating myeloproliferative disorders
WO2025002346A1 (zh) 含pd-l1小分子抑制剂的药物组合及其应用
CN117442738A (zh) 一种联合用药物组合物在制备预防或治疗t细胞淋巴瘤的药物中的应用
WO2024240025A1 (zh) 一种联合用药物组合物及其应用
WO2024192139A1 (en) Combination treatment of chronic myelomonocytic leukemia in patients with ras pathway mutations
CN118453614A (zh) 一种改善或治疗滤泡性淋巴瘤的联合用药物组合物及其应用
KR20160049312A (ko) 항암제 부작용의 경감용 조성물

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20210623

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20211117

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240419

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20240627

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

AMND Amendment
PX0901 Re-examination

Patent event code: PX09012R01I

Patent event date: 20240822

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20240830

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20241202

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20241203

End annual number: 3

Start annual number: 1

PG1601 Publication of registration